With the IPO market as bad as it's ever been and acquisitions uncertain, VCs are looking around for alternative exits for their late-stage companies. One strategy being discussed: selling their late-stage start-ups, to PE-backed private-company acquirers -- acquirers which are by and large still to be created. These mega-startups would have access to plenty of capital (just not public capital) and would be looking to build businesses all the way to profitability, at which point these could be sold to someone else or go public in a very liquid offering. But while there's enough money in private equity to accomplish the strategy, it's hardly straightforward - and for now the talk of this alternative path to liquidity through private equity is just that: talk.
Historically speaking, the first half of 2008 has not been the
worst period for biotech IPOs. But it’s damned close.
So far this year there have been at least two IPOs – Bioheart Inc. (which, after a year of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.
As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.
A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.
A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.
In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
